FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	D.C.	20549
---------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BROWN GREGORY B				2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [AQST]									k all application	able)	g Pers	on(s) to Issu 10% Ov Other (s	vner			
(Last) C/O AQI	,	irst) ΓHERAPEUTIC	(Middle) S, INC.			3. Date of Earliest Transaction (Month/Day/Year) 06/22/2022									below)	give the		below)	poony	
30 TECHNOLOGY DRIVE						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) WARRE	N N.	J	07059										X	Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																	
		Tal	ole I - Non	-Deriv	ative	Se	curitie	s Ac	quired	, Dis	posed o	f, or Be	nefic	ially	Owned					
Dat				Date	Transaction te onth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		e, Transaction Disposed Code (Instr. 5)		ties Acquired (A) d Of (D) (Instr. 3, 4		or 5. Amour Securitie Beneficia Owned F		s Formally (D) (ollowing (I) (I		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) o (D)	r Pri	rice Transacti (Instr. 3 a		on(s)			,moa. 4)	
Common Stock												75,		085		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye		ransac ode (In		of		6. Date Exercisab Expiration Date (Month/Day/Year)		•	7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s Illy	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				c	ode	v	(A)		Date Exercisa	ble	Expiration Date	Title	Amo or Num of Shar	ber						
Stock Option (Right to Purchase)	\$0.7132	06/22/2022			A		25,000		06/22/20:	23 ⁽¹⁾	06/22/2032	Common Stock	25,0	000	\$0	25,000	0	D		

Explanation of Responses:

1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting

Remarks:

/s/ Lori Braender, as Attorney-

In-Fact

** Signature of Reporting Person Date

06/24/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.